We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 0730p CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 5th November 1997 Cambridge Antibody Technology Group plc CAT's collaborative partner Techniclone receives FDA permission to begin clinical trials with TNT for malignant glioma One of CAT's collaborative partners Techniclone Corporation announced earlier today that the US Food and Drug Administration (FDA) has allowed it to begin Phase I Clinical Trials in the US with a radiolabelled chimaeric (part mouse/part human) TNT antibody for the treatment of malignant glioma (the most common primary malignant brain turmour). The Phase I trials are designed to assess the safety of TNT in patients who are to have surgical resection of a recurrent brain tumour. In addition to their treatment, partients will be given imaging doeses of TNT to assess safety of the drug in the body. Endpoints in the study include safety, determination of the maximum tolerated dose and assessment of the patient's response to the injected drug. For further information, please contact: Cambridge Antibody Technology 01763 263 233 David Chiswell Chief Executive Officer John Aston Finance Director Ludgate Communications 0171 253 2252 Andrew Nicolls Nicola How Notes to editors: CAT CAT's business is based on a world leading platform technology for the rapid isolation of human monoclonal antibodies. This technology has applications both in the development of antibody-based human therapeutic products and as a drug discovery tool, particularly in the context of functional genomics. CAT's strategy is to capitalise on the strength of its platform technology in order to build a diverse portfolio of antibody-based human therapeutic products. Clinical trials of two human monoclonal antibodies developed by CAT have already started in 1997. Phase I/IIa Trials of CAT's anti-TGFBeta 2 monoclonal antibody in patients with early proliferative vitreo retinopathy have recently commenced, and earlier this year Phase I/IIa trials of the human anti-TNFAlpha monoclonal antibody isolated and developed by CAT in collaboration with Knoll (BASF) were initiated by Knoll in patients with rheumatoid arthritis. CAT will also continue to use its platform technology as a drug discovery tool, to seek to secure licenses and collaborative agreements with other pharmaceutical companies, including genomics companies, thereby gaining further access to antibody targets of potential therapeutic interest. CAT has already entered into a number of licence and collaborative agreements with pharmaceutical and biotechnology companies. These include: technology licences with Genentech, Pfizer and Eli Lilly; therapeutic antibody licences with Knoll (BASF), Knoll (BASF)/Genetics Institute and Mitsubishi Chemical; joint ventures with Techniclone and ObeSys (with BTG); and a licence agreement with Integra Life Sciences. Tumour Necrosis Therapy (TNT) TNT is a process whereby radiolabelled antibodies are targeted at necrotic tissue found at the core of solid tumours. As such it has the potential to kill growing tumour cells without attaching to surrounding healthy tissue. TNT acts by binding to the necrotic cells at the core of the tumour and irradiating the tumour from the inside. Techniclone and CAT Techniclone, a Californian company, and CAT have a collaborative joint venture to exploit TNT. Revenues and costs are broadly shared (except that Techniclone retains manufacturing rights). The programme involved the development of both chimaeric and human antibodies.The human antibody, which is in the pre- clinical stage of development, is intended for systemic application and in vivo imaging. END MSCAVONKBSKARAA
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions